首页 | 本学科首页   官方微博 | 高级检索  
检索        

血塞通注射液联合倍他司汀治疗后循环性缺血眩晕的疗效观察
引用本文:杨明华,樊素娟.血塞通注射液联合倍他司汀治疗后循环性缺血眩晕的疗效观察[J].现代药物与临床,2017,32(5):784-787.
作者姓名:杨明华  樊素娟
作者单位:1. 南阳市第九人民医院药剂科,河南南阳,473065;2. 南阳市卫生学校第二附属医院神经内科,河南南阳,473000
摘    要:目的探讨血塞通注射液联合盐酸倍他司汀治疗后循环缺血性眩晕的临床疗效。方法选取2015年10月—2016年10月在南阳市第九人民医院进行治疗的后循环缺血性眩晕患者94例,根据治疗方案的不同分为对照组(47例)和治疗组(47例)。对照组静脉滴注盐酸倍他司汀注射液,20 mg加入5%葡萄糖溶液250 m L中,1次/d。治疗组在对照组的基础上静脉滴注血塞通注射液,10 m L加入5%葡萄糖溶液250 m L中,1次/d。两组患者均连续治疗2周。观察两组患者临床疗效,同时比较治疗前后两组患者椎基底动脉平均血流速度、血液流变学指标和眩晕症状评分变化。结果治疗后,对照组和治疗组的总有效率分别为80.85%、95.74%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者左、右椎动脉及基底动脉平均血流速度均较治疗前明显升高(P0.05);且治疗后治疗组椎基底动脉平均血流速度改善更显著(P0.05)。治疗后,两组患者全血黏度(WBV)、血浆黏度(PV)、纤维蛋白原(FIB)和血小板黏附率(PAR)等指标均较治疗前显著降低(P0.05);且治疗后治疗组患者的血液流变学指标水平显著优于对照组(P0.05)。治疗后,两组患者眩晕症状评分均明显降低(P0.05);且治疗后治疗组患者眩晕症状评分降低程度显著优于对照组(P0.05)。结论血塞通注射液联合盐酸倍他司汀治疗后循环缺血性眩晕的临床效果显著,可明显改善患者眩晕症状,增加椎基底动脉血供,降低血液黏度。

关 键 词:血塞通注射液  盐酸倍他司汀注射液  后循环缺血性眩晕  血液流变学  眩晕症状评分
收稿时间:2017/1/10 0:00:00

Clinical study on Xuesaitong Injection combined with betahistine in treatment of posterior circulation ischemia vertigo
YANG Ming-hua and FAN Su-juan.Clinical study on Xuesaitong Injection combined with betahistine in treatment of posterior circulation ischemia vertigo[J].Drugs & Clinic,2017,32(5):784-787.
Authors:YANG Ming-hua and FAN Su-juan
Institution:Department of Pharmacy, The Ninth People''s Hospital of Nanyang, Nanyang 473065, China;Department of Neurology, The Second Affiliated Hospital of Nanyang Health School, Nanyang 473000, China
Abstract:Objective To investigate the clinical effect of Xuesaitong Injection combined with betahistine in treatment of posterior circulation ischemia vertigo. Methods Patients (94 cases) with posterior circulation ischemia vertigo in the Ninth People''s Hospital of Nanyang from October 2015 to October 2016 were divided into control (47 cases) and treatment (47 cases) groups based on different treatments. Patients in the control group were iv administered with Betahistine Hydrochloride Injection, 20 mg added into 5% glucose solution (250 mL), once daily. Patients in the treatment group were iv administered with Xuesaitong Injection on the basis of the control group, 10 mL added into 5% glucose solution (250 mL), once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies in two groups were evaluated, the changes of average blood flow velocity of vertebrobasilar artery, hemorheology index, and vertigo symptom score in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.85% and 95.74% respectively, and there was difference between two groups (P < 0.05). After treatment, the mean blood flow velocity of left and right vertebral artery and basilar artery in two groups was significantly increased (P < 0.05). And the average blood flow velocity of vertebrobasilar artery in the treatment group was increased more significantly than that in the control group (P < 0.05). After treatment, the WBV, PV, FIB, and PAR in two groups were significantly decreased (P < 0.05). And the hemorheology index in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the vertigo symptom scores in two groups were significantly decreased (P < 0.05). And the decrease degree of vertigo symptom score in treatment group was significantly better than that in the treatment group (P < 0.05). Conclusion Xuesaitong Injection combined with betahistine has significant clinical effect in treatment of posterior circulation ischemia vertigo, can obviously improve the vertigo symptoms and increase basilar artery blood supply with reducing blood viscosity.
Keywords:Xuesaitong Injection  Betahistine Hydrochloride Injection  posterior circulation ischemic vertigo  hemorheology  vertigo symptom score
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号